How HMOs & Lactoferrin Support Lifelong Gut Health

Key takeaways

• Infants: A randomized controlled trial (RCT) of formula with 2′-fucosyllactose (2′-FL) + lacto-N-neotetraose (LNnT) cut bronchitis cases by ~82% at 4 months and lowered antibiotic use by ~31% through 12 months versus control. ^[1]
• Adults: HMOs (2′-FL/LNnT) selectively increase Bifidobacterium in IBS without worsening symptoms (RCT) and improved symptom severity and quality of life in a multicenter open-label trial. ^[2][3]
• Lactoferrin: Meta-analysis of RCTs in adults shows 43% lower odds of respiratory infections with lactoferrin. ^[6] A separate meta-analysis in H. pylori therapy raised eradication rates from 74.4% to 86.6% (≈16% relative increase) and reduced side effects by ≈44%. ^[5]
• Preterm infants: Updated Cochrane review suggests lactoferrin may reduce late-onset sepsis (evidence quality varies; large ELFIN RCT found no benefit). ^[7][8]
• kēpos approach: We pair bio-identical HMOs with human milk lactoferrin (hmLF) to support the gut–immune–iron axis in adults, building on the same biology that supports infants.

Why human milk bioactives matter beyond infancy

Human milk oligosaccharides (HMOs) and lactoferrin are two of the most studied bioactives in human milk. HMOs are precision prebiotics that selectively feed beneficial microbes like Bifidobacterium, supporting gut barrier integrity and balanced immune signaling. Lactoferrin is an iron-binding glycoprotein that shapes the mucosal environment, supports innate immunity, and helps manage iron without the GI side effects common to many iron salts.

For a friendly primer on each, see: HMOs: A Prebiotic Game-Changer, How Human Milk Lactoferrin Supports Adults, and our overview of the category: Human Milk Supplementation | A New Health Category?

Infant health: HMO RCTs show fewer infections and less medication use

In a double-blind RCT of healthy infants fed a formula supplemented with 2′-FL + LNnT, investigators reported markedly lower infection-related outcomes versus control. Specifically, bronchitis incidence was 2.3% vs 12.6% by 4 months (≈82% relative reduction), 6.8% vs 21.8% by 6 months (≈69% reduction), and 10.2% vs 27.6% by 12 months (≈63% reduction). Lower respiratory tract infections were 19.3% vs 34.5% through 12 months (≈44% reduction). Antibiotic use was reduced to 34.1% vs 49.4% at 6 months and 42.0% vs 60.9% at 12 months (≈31% reductions), with similar reductions for antipyretic use. ^[1]

Bottom line: Early-life HMOs don’t just “feed good bugs”—they’re associated with fewer infections and less medication during the critical first year.

Adult gut & immune support: HMOs + lactoferrin

HMOs in adults

In IBS, a randomized, double-blind study found that a 4:1 mix of 2′-FL/LNnT significantly increased fecal Bifidobacterium without worsening GI symptoms, supporting the concept of selective prebiotic action for comfort-sensitive guts. ^[2] A multicenter open-label trial (n=317) reported a 55% reduction in IBS Symptom Severity Score (323 → 144) and a ~48% improvement in health-related quality-of-life scores over 12 weeks. ^[3]

A recent randomized trial in older adults (12 weeks) also confirmed bifidogenic effects of an HMO blend (5 g/day) and reported favorable shifts in metabolic markers like fasting insulin, HDL cholesterol, and FGF21—consistent with improved metabolic–microbiome crosstalk. ^[4]

Want a quick compare against probiotics? See HMOs + effera™ lactoferrin vs probiotics.

Lactoferrin in adults

A meta-analysis of randomized trials adding lactoferrin to standard Helicobacter pylori therapy increased eradication from 74.4% to 86.6% (absolute +12.1 points; ≈16% relative increase) and reduced side effects from 16.3% to 9.1% (≈44% relative reduction). ^[5]

For respiratory health, a 2021 meta-analysis of RCTs (n=1,194) found lactoferrin users had 43% lower odds of developing respiratory tract infections versus control (pooled OR 0.57, 95% CI 0.44–0.74). ^[6]

For iron biology, RCTs and meta-analyses indicate oral lactoferrin can be as effective or superior to ferrous sulfate at improving hemoglobin and ferritin with fewer GI side effects—an important advantage for adherence. ^[9][10]

Curious how hmLF differs from other forms? Start here: What is effera™ hmLF?

Preterm infants: where lactoferrin stands today

Evidence has evolved. A 2020 Cochrane update suggested lactoferrin (with or without probiotics) may reduce late-onset sepsis, though certainty ranged from low to moderate and results varied by trial design. ^[7] The large ELFIN RCT (>2,200 infants) reported no significant reduction in late-onset infection with bovine lactoferrin. ^[8] A 2023 network meta-analysis across 25,840 infants found the largest reductions in morbidity with multi-strain probiotics, while combinations that included lactoferrin also ranked favorably for some outcomes. ^[11]

Translation: lactoferrin shows promise but results differ across studies; combinations and context matter.

Why kēpos uses HMOs + human milk lactoferrin (hmLF)

Our blends follow the biology: HMOs (selective prebiotic fuel) help nudge the microbiome toward a Bifidobacterium-rich, low-gas state; hmLF helps shape a more resilient mucosal environment and supports iron handling—without the “iron-gut” tradeoffs. Learn more on: Benefits, The Proof, and our product page: kēpos Human Milk-Equivalent Superfood.

FAQ

Are HMOs safe for adults?

Yes. RCTs in IBS and older adults report good tolerability with selective microbiome effects (notably increased Bifidobacterium). ^[2][4]

Is hmLF the same as bovine lactoferrin?

Human milk lactoferrin (hmLF) is the native human form. Where adult outcome data use bovine LF (most RCTs to date), we cite those. Recombinant human LF (effera™) has emerging adult safety data in randomized trials, supporting its use as a food ingredient. ^[12]

Can I take HMOs + lactoferrin together?

That’s the idea behind kēpos: pair a precision prebiotic (HMOs) with hmLF to support the gut–immune–iron axis in one scoop. Always consult your clinician if you have medical conditions or take medications.

References

1. Puccio G, et al. J Pediatr Gastroenterol Nutr. 2017;64(4):624–631. PubMed (PMID: 28107288). 
2. Iribarren C, et al. Neurogastroenterol Motil. 2020;32(10):e13920. PubMed (PMID: 32536023). 
3. Palsson OS, et al. Clin Transl Gastroenterol. 2020;11(12):e00276. PubMed (PMID: 33512807). 
4. Carter SM, et al. Am J Clin Nutr. 2025;121(6):1196–1206. PubMed (PMID: 40738103). 
5. Zhu X, et al. Clin Res Hepatol Gastroenterol. 2010;34(2):124–131 (meta-analysis; received 2009). PubMed (PMID: 19298339). 
6. Ali AS, et al. Clin Nutr ESPEN. 2021;46:12–19 (meta-analysis). PubMed (PMID: 34620326).
7. Pammi M, Suresh G. Cochrane Review Update. Cochrane Database Syst Rev. 2020;3:CD007137. PubMed (PMID: 32232984). 
8. ELFIN Trial (UK) overview. Neonatology. 2020;117(6):673-680. PubMed (PMID: 32830532).
9. Zhao X, et al. Nutrients. 2022;14(5):1042 (meta-analysis). PubMed (PMID: 35276902).
10. Nappi C, et al. Acta Obstet Gynecol Scand. 2009;88(8):879–884 (RCT). PubMed (PMID: 19639462).
11. Wang Y, et al. JAMA Pediatr. 2023;177(11):1158–1167 (network meta-analysis across 25,840 preterm infants). PubMed (PMID: 37782505). 
12. Peterson RD, et al. Int J Toxicol. 2025 (randomized, double-blind safety/immunogenicity of effera™ rhLF vs bLF). PubMed (PMID: 39465888). 

Notes: Where adult outcome RCTs on hmLF specifically are still emerging, we cite the closest high-quality evidence (bovine LF or combination therapies). Always consult a clinician for personal medical decisions.